New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
12:43 EDTZGNXZogenix calls news reports on Zohydro 'false and misleading'
Zogenix disclosed that on March 20 it issued a letter from its CEO to stakeholders addressing certain statements that have been made about the company and its product, Zohydro ER extended-release capsules. The letter stated in part, "An increasing number of news reports have been including false and misleading statements about our company and our product, Zohydro ER extended-release capsules, the first and only extended release hydrocodone product without acetaminophen. This misinformation has created negative perceptions about Zohydro ER, which was approved by the FDA in October 2013 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate...In reality, any drug that is not used as prescribed presents a danger to the person abusing the medicine...We further would like to note that without justification, inaccurate allegations have been made that Zogenix paid a university to arrange meetings with the FDA to secure approval of Zohydro ER...On behalf of severe chronic pain sufferers who will potentially benefit from Zohydro ER, we will continue to move aggressively to correct these false and misleading statements. The plight of people living with severe chronic pain should not be politicized. We encourage representatives of the news media who are reporting on Zohydro ER to contact us directly and we will gladly share the facts."
News For ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ZGNX

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use